Mylan Inc. (MYL) said it has entered into a settlement agreement with Teva that will resolve pending patent litigation related to Nuvigil (Armodafinil Tablets, 50 mg, 150 mg, and 250 mg).
The settlement allows Mylan to begin selling generic versions of 50 mg, 150 mg, and 250 mg Nuvigil under license beginning in June 2016, or earlier under certain circumstances. Pursuant to the agreement, pending litigation will be dismissed.
Mylan stated that other details of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
For comments and feedback: editorial@rttnews.com